In April 2025, the FDA granted orphan drug designation to spesolimab-sbzo for the treatment of pyoderma gangrenosum. This ...

At the low end, the drugs include $119,000 a year to treat certain rare genetic disorders. At the high end: a gene therapy ...

Then, in June, B.C.’s NDP government ended her treatment.